Drugs / STG-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04489511 | Oct 2020 → Apr 2021 | Stargardt disease | Stargazer Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STG-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04489511 ↗ |
| Modality | Small molecule | — CHEMBL4650305 ↗ |
| Route | Oral | “STG-001 given orally at Dose 1 once a day for 28 days” NCT04489511 ↗ |